JP4689959B2 - セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用 - Google Patents

セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用 Download PDF

Info

Publication number
JP4689959B2
JP4689959B2 JP2003546936A JP2003546936A JP4689959B2 JP 4689959 B2 JP4689959 B2 JP 4689959B2 JP 2003546936 A JP2003546936 A JP 2003546936A JP 2003546936 A JP2003546936 A JP 2003546936A JP 4689959 B2 JP4689959 B2 JP 4689959B2
Authority
JP
Japan
Prior art keywords
compound
sucrose
dogs
sodium salt
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003546936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511642A (ja
JP2005511642A5 (enExample
Inventor
ロジャー・ネルソン・キムブル
レヌカ・デヴィ・レディ
イヴゲニー・ユーレヴィッチ・シャラーエフ
サイモン・エドワード・ブランチフラワー
ブライアン・スコット・ブロンク
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2005511642A publication Critical patent/JP2005511642A/ja
Publication of JP2005511642A5 publication Critical patent/JP2005511642A5/ja
Application granted granted Critical
Publication of JP4689959B2 publication Critical patent/JP4689959B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2003546936A 2001-11-30 2002-11-13 セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用 Expired - Lifetime JP4689959B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33853601P 2001-11-30 2001-11-30
US60/338,536 2001-11-30
US39893202P 2002-07-26 2002-07-26
US60/398,932 2002-07-26
PCT/IB2002/004743 WO2003045435A1 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs

Publications (3)

Publication Number Publication Date
JP2005511642A JP2005511642A (ja) 2005-04-28
JP2005511642A5 JP2005511642A5 (enExample) 2006-01-12
JP4689959B2 true JP4689959B2 (ja) 2011-06-01

Family

ID=26991236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003546936A Expired - Lifetime JP4689959B2 (ja) 2001-11-30 2002-11-13 セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用

Country Status (27)

Country Link
US (1) US7378408B2 (enExample)
EP (1) EP1448234B1 (enExample)
JP (1) JP4689959B2 (enExample)
KR (1) KR100621291B1 (enExample)
CN (1) CN100502873C (enExample)
AR (1) AR037595A1 (enExample)
AT (1) ATE406916T1 (enExample)
AU (1) AU2002348986B2 (enExample)
BR (1) BRPI0214583B1 (enExample)
CA (1) CA2468708C (enExample)
CY (1) CY1108437T1 (enExample)
DE (1) DE60228749D1 (enExample)
DK (1) DK1448234T3 (enExample)
EA (1) EA008503B1 (enExample)
ES (1) ES2307800T3 (enExample)
HR (1) HRP20040487A2 (enExample)
IL (2) IL161851A0 (enExample)
IS (1) IS7214A (enExample)
MA (1) MA27085A1 (enExample)
MX (1) MXPA04003724A (enExample)
NO (1) NO334818B1 (enExample)
NZ (1) NZ532208A (enExample)
PL (1) PL212683B1 (enExample)
PT (1) PT1448234E (enExample)
TN (1) TNSN04097A1 (enExample)
TW (1) TWI248363B (enExample)
WO (1) WO2003045435A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021725A1 (it) 2002-08-01 2002-10-31 Zambon Spa Composizioni farmaceutiche ad attivita' antibiotica.
US20080096858A1 (en) * 2004-04-22 2008-04-24 University Of Connecticut Method of Stabilizing Disordered Cefovecin Sodium Salt
EP1656930A1 (en) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
WO2006064516A1 (en) * 2004-12-17 2006-06-22 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
CA2597812C (en) * 2005-02-14 2012-01-24 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
ATE472996T1 (de) * 2005-10-29 2010-07-15 Intervet Int Bv Cefquinomzusammensetzungen und verfahren zu ihrer verwendung
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
WO2009111422A2 (en) * 2008-03-04 2009-09-11 Elan Pharmaceuticals, Inc. Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20110150765A1 (en) 2008-10-31 2011-06-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Frozen compositions and methods for piercing a substrate
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274994A1 (en) * 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Stabilizing ceftolozane
WO2017007515A1 (en) * 2015-07-09 2017-01-12 Universal Nutrients, Llc Pharmaceutical compositions
JP7020913B2 (ja) 2015-09-07 2022-02-16 持田製薬株式会社 アルギン酸凍結乾燥製剤
EP3687993A1 (en) 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
EP3687992A1 (en) 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivatives and production process thereof
CN111447924A (zh) * 2017-09-27 2020-07-24 费多拉制药公司 二氮杂二环辛烷衍生物的药物形式及其制备方法
GB2575261B (en) 2018-07-02 2022-03-09 Norbrook Lab Ltd Intermediates in the synthesis of C3-substituted cephalosporins
CN109393004A (zh) * 2018-09-28 2019-03-01 上海锦立保鲜科技有限公司 一种利用冻品自由水升华实现真空解冻的方法
CN118284438A (zh) * 2021-11-26 2024-07-02 安斯泰来制药株式会社 含有吲哚菁化合物的固体药物组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002748A (en) * 1976-01-19 1977-01-11 Eli Lilly And Company Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS6045514A (ja) * 1983-08-22 1985-03-12 Shionogi & Co Ltd 安定な抗菌性凍結乾燥製剤
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
US5138066A (en) * 1987-08-14 1992-08-11 Hoffmann-La Roche, Inc. Intermediates for cephalosporins with sulfur-containing oxyimino side chain
NZ227842A (en) 1988-02-05 1990-12-21 Lilly Co Eli Crystalline 2.5-hydrate form of a beta-lactam
CA2024587A1 (en) * 1989-09-05 1991-03-06 Bernard Ecanow Drug delivery compositions based on biological cells or components thereof and methods
US6001997A (en) * 1990-07-24 1999-12-14 Bateson; John Hargreaves Cephalosporins and homologues, preparations and pharmaceutical compositions
MY106399A (en) * 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
US6020329A (en) * 1990-07-24 2000-02-01 Pzifer Inc. Cephaloporins and homologues, preparations and pharmaceutical compositions
US5401842A (en) * 1992-09-08 1995-03-28 Bristol-Myers Squibb Company Injectable compositions of a cephalosporin dihydrate salt
EP0664117A1 (de) * 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposomenlösungen
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
KR100312622B1 (ko) * 1998-11-03 2002-02-28 김송배 생약을주성분으로한안정화된항암제조성물및그제조방법
JP2001199889A (ja) * 1999-11-11 2001-07-24 Takeda Chem Ind Ltd 縮合ピリダジン誘導体を含有してなる点鼻用剤
EP1246668B1 (en) 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
GB0002835D0 (en) * 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
GB0019124D0 (en) 2000-08-03 2000-09-27 Pfizer Novel process
RU2237670C1 (ru) * 2000-12-04 2004-10-10 Пфайзер Продактс Инк. Способ взаимодействия и промежуточные продукты, пригодные для получения цефалоспоринов

Also Published As

Publication number Publication date
AU2002348986B2 (en) 2008-04-03
AR037595A1 (es) 2004-11-17
JP2005511642A (ja) 2005-04-28
EA008503B1 (ru) 2007-06-29
ATE406916T1 (de) 2008-09-15
CA2468708C (en) 2008-08-19
IL161851A0 (en) 2005-11-20
CY1108437T1 (el) 2014-04-09
DK1448234T3 (da) 2008-11-03
TW200300351A (en) 2003-06-01
EA200400489A1 (ru) 2004-10-28
MA27085A1 (fr) 2004-12-20
IL161851A (en) 2011-11-30
US20030186957A1 (en) 2003-10-02
ES2307800T3 (es) 2008-12-01
PL370083A1 (en) 2005-05-16
BRPI0214583B1 (pt) 2015-11-17
BR0214583A (pt) 2004-11-03
CN100502873C (zh) 2009-06-24
PT1448234E (pt) 2008-10-02
PL212683B1 (pl) 2012-11-30
HK1071292A1 (zh) 2005-07-15
KR20040058345A (ko) 2004-07-03
KR100621291B1 (ko) 2006-09-13
TWI248363B (en) 2006-02-01
WO2003045435A1 (en) 2003-06-05
DE60228749D1 (de) 2008-10-16
CN1604793A (zh) 2005-04-06
NZ532208A (en) 2007-01-26
NO334818B1 (no) 2014-06-02
EP1448234A1 (en) 2004-08-25
NO20042271L (no) 2004-07-22
TNSN04097A1 (fr) 2006-06-01
CA2468708A1 (en) 2003-06-05
US7378408B2 (en) 2008-05-27
AU2002348986A1 (en) 2003-06-10
MXPA04003724A (es) 2005-04-08
IS7214A (is) 2004-04-07
EP1448234B1 (en) 2008-09-03
HRP20040487A2 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
JP4689959B2 (ja) セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用
JP7177314B2 (ja) セフトロザン抗生物質組成物
EP1671635B1 (en) Noncrystalline antibacterial composition containing cefditoren pivoxil
NZ551403A (en) Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
ZA200403933B (en) Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
HK1071292B (en) Formulations comprising a cephalosporin compound
Radwanski et al. Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid Mylanta double-strength liquid or with ranitidine
AU2015200599A1 (en) Ceftolozane Antibiotic Compositions
US20030149013A1 (en) Methods of treating bacterial infections in dogs and cats
JP2005524611A (ja) イヌ及びネコにおける細菌感染の治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051111

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081106

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100527

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100705

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110124

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110217

R150 Certificate of patent or registration of utility model

Ref document number: 4689959

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140225

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140225

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term